RxDoctor Payments Data

Jeffrey Ma, MD

Cornea and External Diseases Specialist · Sacramento, CANPI 1750709648

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Alcon accounts for 62.1% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2024 at $498 and has fallen 77.2% since, to $114 in 2025. That places this record below the midpoint for cornea and external diseases specialist clinicians in CA, where the typical reported total is $4,024.

$1,366in general payments, 2019–2025

Across 25 payments — averaging $54.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$848
  • Biotissue Holdings Inc.$346
  • Harrow Eye, LLC$115
  • GSK$23
  • Sight Sciences, Inc.$21
  • Shire North American Group Inc$12

What the payments were for

  • Food & beverage$1,366100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,366 in reported general payments places this provider in the 25th percentile of 50 cornea and external diseases specialist providers in California.

See all cornea and external diseases specialist providers in California

Medicare billing

Part B allowed, 2024
$335,078
Medicare patients
923
Services billed
3,082

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MieboPerfluorohexyloctane/Pf48$50,352
RestasisCyclosporine63$47,810
Cyclosporine91$43,910
XiidraLifitegrast25$24,308
LumiganBimatoprost35$22,176
Prednisolone Acetate293$10,852
Latanoprost402$7,641
Fluorometholone89$6,578
Travoprost25$4,421
MoxifloxacinMoxifloxacin Hcl222$4,184
Doxycycline Hyclate63$2,482
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat94$2,096
ErythromycinErythromycin Base108$1,370
Timolol Maleate112$1,082
Brimonidine Tartrate62$993

Paid to pharmacies, not to this prescriber.

Other cornea and external diseases specialist in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →